Mitoxantrone is superior to doxorubicin in a multiagent weekly regimen for patients older than 60 with high-grade lymphoma: results of a BNLI randomized trial of PAdriaCEBO versus PMitCEBO.
暂无分享，去创建一个
K. Maclennan | W. Gregory | P. Hoskin | D. Cunningham | P. Mainwaring | D. Linch | B. Hancock | A. Norton | P. Smith | G. Hudson | Ken MacLennan | Peter Hoskin | D. Linch | B. Hancock | Paul N. Mainwaring | David Cunningham | Paul Smith | G. Hudson | Walter M. Gregory | Andrew J. Norton